Sichuan Biokin Pharma Says Co Remains Eligible for up to $250 Mln Near-Term Payments, up to $7.1 Bln Additional Payments Upon Achieving Specific Development, Regulatory, Commercial Milestones

BRIEF-Sichuan Biokin's Unit Receives $250 Mln Milestone Payment From BMS On Iza-Bren Agreement

Sichuan Biokin Pharma Says Unit Has Received $250 Mln Milestone Payment From Bristol-Myers Squibb Recently Regarding Iza-Bren Global Strategic Agreement

Sichuan Biokin Pharmaceutical (688506.SH) Subsidiary Receives $250 Million Milestone Payment from Bristol-Myers Squibb for Iza-Bren Project

Sichuan Biokin Pharmaceutical Gets Acceptance for Cancer Drug Application

Sichuan Biokin Pharmaceutical Seeks Credit Support from Bank of China Sichuan Branch

Sichuan Biokin Pharma Says Signs Agreement With Bank of China's Sichuan Branch to Receive No Less Than 8 Bln Yuan Worth of Credit

BRIEF-Sichuan Biokin Pharma To Receive Credit Support From Bank Of China

Sichuan Biokin Pharmaceutical (688506.SH): Iza-bren Meets Dual Primary Endpoints in Phase III Trial for Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Biokin's Hong Kong IPO Faces Sudden Setback

Sichuan Biokin Pharma Says It Has Decided to Postpone Hong Kong Listing Due to Current Market Condition

Rare Move: BIOKIN (2615.HK) Delays IPO Just Before Closing—Why?

BRIEF-Sichuan Biokin Pharmaceutical Says Postponement Of Global Offering

Sichuan Biokin Pharmaceutical Postpones Hong Kong IPO

Sichuan Biokin Pharmaceutical - Decided That Global Offering Will Be Postponed and Will Not Proceed Pursuant to Prospectus

Sichuan Biokin Pharmaceutical Co Ltd - Postponement of Global Offering

BIOKIN (02615) Debuts on HKEX with Blockbuster ADC Drug Potential Exceeding $20 Billion

Sichuan Biokin Pharma Launches Up to HK$3.4 Billion Hong Kong IPO

Sichuan Biokin Pharmaceutical (02615) Opens IPO Subscription from Nov 7 to Nov 12, Expected Listing on Nov 17

Biokin Pharmaceutical's T-Bren for Injection Placed in China's List of Breakthrough Therapy Drugs